30 Oct

HealthBeacon Appoints CFO

Irish Digital Health Company Expands Team:  Leading Digital Health Company HealthBeacon, with the world’s first digital Injection Care Management System that drives adherence to therapy for patients on self-administered injectable medications, is delighted to announce the appointment of its new Chief Financial Officer Laurence Flavin to their growing global team. October 2020.

Headquartered in Dublin with additional offices in Boston and Montreal, the company is at a key growth inflection point having secured significant contracts with over 14 major pharmaceuticals, insurance and specialty pharmacies across the globe and implementing its ICMS technology, anchored by its FDA cleared smart sharps bin, in 2020.

Highly experienced CFO and company builder, Laurence Flavin most recently helped build Finance Ireland into Ireland’s largest non-bank lender, raising over €1bn in equity and debt facilities. A qualified chartered accountant, Laurence has a broad base of experience working in capital markets, taking a company public across Dublin and London, and managing corporate transactions.

Commenting on the appointment, Jim Joyce, CEO and Co-Founder, said “Laurence is a talented, driven, financial business leader with a proven reputation of building quality and high growth organisations. His experience in fund raising, scaling companies and working in a highly regulated sector makes him a great fit for HealthBeacon and we are delighted to have him on the team.”

 

HealthBeacon

HealthBeacon’s vision to build smart tools for managing medications saw the launch of the world’s first truly digital enabled Injection Care Management System (ICMS) for the tens of millions of patients taking injectable medications at home. Patients on chronic treatments require digital, virtual and remote support to ensure taking treatment as prescribed and engaging with their condition. Medical Adherence studies have documented that approx. 50% of patients fail on prescribed chronic medications in the first year of treatment, while HealthBeacon’s technology, increases the number of patients that will ultimately succeed on their treatment.

 

Future Health

2020 is witnessing the world’s rapid adoption of digital, virtual and remote healthcare delivery for which HealthBeacon is at the forefront, having developed a leading technology platform for patients on chronic injectable treatment, a market projected to be worth over $300 billion by 2024.

In 2019 HealthBeacon completed a €12m Series A investment round and are in the process of completing an additional financing of between €3-5m anticipated to close in 2020. Investors in HealthBeacon include Enterprise Ireland, Oyster Capital, Cantor Fitzgerald, BVP, Elkstone Partners, Singapore’s SGInnovate and US-based Manatt.

 

For further information contact: Emer O’Reilly, ORPR, T: +353868593658 E: emer@orpr.ie

 

 

About HealthBeacon

HealthBeacon a medication adherence technology company, has developed the World’s first Injection Care Management System for patients that self-administer injectable medication in their homes. HealthBeacon eases the burden of managing patients’ injectable medications from home through their FDA cleared Smart Sharps Bin Technology. With the intervention of HealthBeacon’s Injection Care Management System, patients’ persistence and adherence to medication is increased by 25-30% within twelve months of initiating therapy.  The HealthBeacon integrated model connects a patient’s routine and the prescribing clinician’s workflow.  This technology has been adopted across thirteen countries with >420,000 injections tracked since launch in 2014, with a patient acceptance rate of 80-90%.

For more information or to contact HealthBeacon, visit www.healthbeacon.com or engage with @HealthBeacon on LinkedIn & Twitter.